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1. Introduction 
 
Novel synthetic drugs of abuse, more formally known as new psychoactive substances (NPS), 
are appearing at a rapid pace on recreational drug markets worldwide (Welter-Luedeke and Maurer, 
2016). NPS are designed to imitate the actions of known drugs of abuse (e.g. amphetamines), while 
circumventing current legal restrictions on controlled substances due to their unique chemical 
structures (Baumann et al., 2014). NPS are marketed and sold over the Internet under various names 
like “research chemicals”, “bath salts” or ”legal highs”, and there is legitimate concern about their 
negative impacts on public health (Tettey and Crean, 2015). Based on the surveillance model first 
developed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), the United 
Nations Office on Drugs and Crime (UNODC) launched the Early Warning Advisory (EWA) in 2013 
to monitor the appearance of NPS on a global scale. Recently, the EWA identified 3-
fluorophenmetrazine (3-FPM) as an NPS on Internet websites, and information from drug user forums 
suggests the drug exhibits psychostimulant properties in human users (See Figure 1 for the chemical 
structures of 3-FPM and its positional isomers). Notably, the parent compound phenmetrazine was 
once prescribed as an anorectic medication but was withdrawn from the clinical market because of its 
abuse potential (Griffiths et al., 1976, Banks et al., 2013).  
 The process of developing and manufacturing NPS hinges on easy access to the biomedical 
literature where multiple information sources, such as patent applications and medicinal chemistry 
journals, provide a rich source of ideas for clandestine chemists (Brandt et al., 2014). The preparation 
of 3-FPM was first published in 2011 as part of a patent application for morpholine-based compounds 
that were being investigated for a range of potential therapeutic applications (Blough, 2011, Blough, 
2013). Similar to other psychostimulant drugs, phenmetrazine interacts with plasma membrane 
monoamine transporters (MATs) expressed on the surface of various cell types (Rothman et al., 2002). 
MATs, or neurotransmitter:sodium symporters, belong to the solute carrier 6 family of proteins 
(SLC6) and mediate the uptake of monoamine neurotransmitters from the extracellular space 
(Kristensen et al., 2011). Specific transporters for serotonin (SERT, SLC6A4), dopamine (DAT, 
SLC6A3) and norepinephrine (NET, SLC6A2) exploit the sodium gradient across cell membranes to 
drive the movement of monoamines from the synaptic cleft into the neuronal cytoplasm, thus tightly 
regulating the strength and the duration of monoamine signaling (Torres et al., 2003). MATs represent 
major targets for clinically relevant drugs (e.g., antidepressants) but also for a plethora of abused 
substances, like cocaine and amphetamine (Kristensen et al., 2011). 
 All psychostimulants that target MATs increase extracellular concentrations of monoamines in 
the central and peripheral nervous systems. However, the precise mode of drug action may be 
subdivided into cocaine-like “blockers” and amphetamine-like “releasers” (Sitte and Freissmuth, 
2010). MAT blockers bind to the orthosteric site on transporters and act as non-transported uptake 
inhibitors (Plenge et al., 2012). Cocaine is the prototypical MAT blocker. However, additional 
4 
 
mechanisms for cocaine action have been reported, including monoamine release via reverse transport 
and enhanced exocytosis (Venton et al., 2006, Heal et al., 2014). MAT releasers also bind to 
transporters, but these drugs are subsequently transported into the cytoplasm where they reverse the 
normal direction of transporter flux to trigger efflux of neurotransmitters (Robertson et al., 2009). 
Substrate-type releasers are transported across cellular membranes along with sodium ions and at 
sufficiently high intracellular concentrations, these drugs can redistribute neurotransmitters from 
vesicular storage pools into the cytosol (Sulzer et al., 2005, Sitte and Freissmuth, 2010). As a 
consequence, the intracellular concentrations of free monoamine neurotransmitters and sodium cations 
build up at the inner side of the plasma membrane to enable transporter-mediated reverse transport 
(Sitte and Freissmuth, 2015).  
Previous research shows that phenmetrazine acts as a substrate-type releaser at DAT and NET, 
with much weaker effects at SERT (Rothman et al., 2002). Chemical modification of amphetamine-
type stimulant drugs can produce profound changes in their profile of pharmacological effects. For 
instance, addition of a fluorine to the 4-position on the phenyl ring of amphetamine increases potency 
towards SERT relative to DAT (Marona-Lewicka et al., 1995, Nagai et al., 2007, Baumann et al., 
2011, Rickli et al., 2015). Limited information is available on the pharmacology of 3-FPM (Blough, 
2011, Blough, 2013), so we sought to characterize the molecular mode of action of this drug in cells 
expressing human transporters and in native tissue preparations from rat brain. Based on the available 
structure-activity data for amphetamine-type compounds (Cozzi et al., 2013), we hypothesized that 
addition of a fluoro substitution to the phenyl ring of phenmetrazine would enhance the potency of 
analogs toward SERT compared to DAT. In vitro uptake inhibition and efflux assays were used to 
elucidate the mechanism of action of 3-FPM at MATs, and to evaluate whether the drug induces 
transporter-mediated release consistent with an amphetamine-type action. Two positional isomers, 2-
FPM and 4-FPM, were included in our study for comparison, because isomers of NPS often appear in 
the marketplace and present challenges from a clinical and forensic perspective (Brandt et al., 2015, 
Brandt et al., 2014, Elliott et al., 2013, Dinger et al., 2016, Marusich et al., 2016, McLaughlin et al., 
2016).  
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2. Materials and Methods 
 
2.1 Reagents and Chemicals 
2-(2-Fluorophenyl)-3-methylmorpholine (2-FPM), 2-(3-fluorophenyl)-3-methylmorpholine (3-FPM) 
and 2-(4-fluorophenyl)-3-methylmorpholine (4-FPM) were prepared as fumarate salts and analytically 
characterized previously (McLaughlin et al., 2016). [
3
H]5HT (28.3 µCi mmol
-1
) was purchased from 
PerkinElmer (Boston, MD, USA), and [
3
H]MPP
+
 (80-85 µCi mmol
-1
) was purchased from American 
Radiolabeled Chemicals (St. Louis, MO, USA). Cell culture dishes were from Sarstedt AG&Co., 
Nuembrecht, Germany. All other chemicals and reagents, including cell culture supplies, were 
purchased from Sigma Aldrich.  
 
2.2 Cell Culture 
Human embryonic kidney (HEK293) cells were maintained in Dulbecco’s Modified Essential Medium 
(DMEM), supplemented with 10% fetal calf serum, streptomycin (100 µg 100 mL
-1
) and penicillin 
(100 IU 100 mL
-1
), and kept in humidified atmosphere (5 % CO2, 37 °C). The generation of HEK293 
cells stably expressing human DAT (hDAT) and human NET (hNET) is described elsewhere (Scholze 
et al., 2002). Human SERT (hSERT) was cloned in frame with monomeric GFP (mGFP) into a 
tetracycline inducible expression vector pcDNA 4/TO (Invitrogen by life-Technologies, Carlsbad, CA, 
USA). The generation of stable cell lines was performed as described previously (Hilber et al., 2005). 
The selection of HEK293 cells stably expressing hDAT or hNET was executed by constantly adding 
geneticin (50 µg mL
-1
). For hSERT expressing HEK293 cells the selection pressure was maintained by 
adding blasticidin (10 µg mL
-1
) and zeocin (300 µg mL
-1
) to the cell culture medium. Expression of 
hSERT was induced with tetracycline (1 µg mL
-1
) 24 h prior to the experiment. 
 
2.3 Radiotracer Uptake and Efflux Experiments in HEK293 Cells 
Uptake inhibition and efflux experiments were performed as described elsewhere (Mayer et al., 2017). 
Briefly, for uptake experiments, HEK293 cells expressing the desired transporter were seeded at a 
density of 4 x10
4
 cells per well on a poly-D-lysine (PDL) coated 96-well plate the day before the 
experiment. The cells were incubated for 5 min with various concentrations of 2-, 3- or 4-FPM in 
Krebs-HEPES buffer (KHB) (25 mM Hepes, 120 mM NaCl, 5 mM KCl, 1.2 mM CaCl2, 1.2 mM 
MgSO4 and 5 mM D-glucose, pH 7.3) to allow for equilibration before the addition of radiolabeled 
substrate. The radiolabeled substrate for hDAT and hNET was [
3
H]MPP
+
 (20 nM) whereas the 
radiolabeled substrate for hSERT was [
3
H]5HT (100 nM). After incubation for 180 s (hDAT and 
hNET) or 60 s (hSERT), radioactive substrate was aspirated and the cells were washed with ice cold 
KHB to terminate uptake. Subsequently, the cells were lysed in sodium dodecylsulfate (SDS, 1 %; 200 
µL per well) and the amount of radioactivity within each well was assessed by use of a liquid 
scintillation counter. Nonspecific uptake was determined in the presence of 10 µM mazindol for 
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hDAT and hNET or 10 µM paroxetine for hSERT. For analysis, nonspecific uptake was subtracted 
from all values and uptake was expressed as percent of control uptake, i.e. uptake in absence of 
inhibitor, and plotted against increasing concentrations of inhibitor.  
For efflux experiments, 4 x10
4
 HEK293 cells expressing hDAT, hNET or hSERT were seeded 
onto PDL-coated 5mm glass-coverslips. The cells were pre-loaded with 0.1 µM [
3
H]MPP
+
 (hDAT and 
hNET) or 0.4 µM [
3
H]5HT (hSERT) in KHB for 20 min at 37°C. Subsequently, the cells were 
transferred into small chambers with a volume of 200 µL and superfused with KHB (25°C, 0.7 mL per 
minute) for 40 min to establish a stable baseline. At t= -12, the experiment was started by collecting 
three 2-min fractions of superfusate to record the basal efflux, followed by the addition of monensin 
(10 µM) (at t= -8) or solvent for four fractions. Finally, the cells were exposed to 2-, 3- or 4-FPM (5 
µM) (at t=0) for five fractions and then lysed in 1% SDS. Radioactivity was determined by liquid 
scintillation counting and radioactivity per fraction was expressed as fractional release, i.e. the 
percentage of released [
3
H] versus the amount of [
3
H] present at the beginning of that fraction (Sitte et 
al., 2000).  
 
2.4 Whole-cell Patch Clamp 
Whole-cell Patch Clamp: HEK293 cells stably expressing hSERT were seeded at low density 24 h 
before recordings. Currents through the transporter were measured in the whole-cell patch clamp 
configuration. The electrode resistance was between 2–5 megohms. For the recordings, we used the 
following internal solution: 133 mM potassium gluconate, 6 mM NaCl, 1 mM CaCl2, 0.7 mM MgCl2, 
10 mM EGTA, and 10 mM HEPES adjusted to pH 7.2 with KOH. The external solution in all 
experiments was 140 mM NaCl, 3 mM KCl, 2.5 mM CaCl2, 2 mM MgCl2, 20 mM glucose, and 10 
mM HEPES adjusted to pH 7.4 with NaOH. For rapid solution exchange, we used an OctaFlow 
superfusion device (ALA Scientific, Farmingdale, NY). Cells were clamped to -60mV and 
continuously superfused either with blank external solution or an external solution containing the 
tested compounds. For current acquisition, we employed an Axopatch 200B amplifier and pClamp 
10.2 software (Molecular Devices, Sunnyvale, CA). The washout period following substrate/inhibitor 
application was 60 s in all cases. Current traces were filtered at 1 kHz and digitized at 10 kHz using a 
Digidata 1550 (Molecular Devices). The currents were quantified using Clampfit 10.2 software. 
Passive holding currents were subtracted, and the traces were filtered using a 100-Hz digital Gaussian 
low-pass filter. 
 
2.5 Radiotracer flux experiments in rat brain synaptosomes 
All experiments utilizing animal tissue were performed in agreement with the ARRIVE guidelines. 
Male Sprague-Dawley rats (Harlan, Frederick, MD, US) weighing 250-350 g were maintained in 
facilities fully accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care, and experiments were performed in accordance with the Institutional Animal Care and Use 
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Committee at the National Institute on Drug Abuse (NIDA), Intramural Research Program (IRP). Rats 
were double-housed and maintained on a 12 h light:dark cycle (lights on from 7:00 AM to 7:00 PM), 
with food and water available ad libitum. On the day of an experiment, rats were euthanized by CO2 
narcosis and brains were processed to yield synaptosomes as previously described (Rothman et al., 
2002). Brain tissue was obtained between 10:00 AM and noon for all experiments. Synaptosomes 
were prepared from rat striatum for the DAT assays, whereas synaptosomes were prepared from whole 
brain minus striatum and cerebellum for the NET and SERT assays. For the release assays, 9 nM 
[
3
H]MPP
+
 was used to assess activity at DAT and NET while 5 nM [
3
H]5-HT was used to assess 
activity at SERT. All buffers used in the release assays contained 1 µM reserpine to block vesicular 
uptake of substrates. The selectivity of release assays was optimized for a single MAT by including 
unlabeled blockers to prevent uptake of substrates by competing transporters. Specifically, for NET 
assays, 100 nM GBR12935 and citalopram were added; for SERT assays, 100 nM GBR12935 and 
nomifensine were added; for DAT assays, 100 nM desipramine and citalopram were added. 
Synaptosomes were preloaded with radiolabeled substrate in Krebs-phosphate buffer (126 mM NaCl, 
2.4 mM KCl, 0.5 mM KH2PO4, 1.1 mM CaCl2, 0.83 mM MgCl2, 0.5 mM Na2SO4, 11.1 mM glucose, 
13.7 mM Na2HPO4, 1 mg per mL ascorbic acid, and 0.05 mM pargyline, pH 7.4) and incubated for 1 h 
to achieve steady state. Release assays were initiated by adding 850 µL of preloaded synaptosomes to 
150 µL of test compound prepared in Krebs-phosphate buffer containing 1 mg mL
-1
 BSA. Maximal 
release was determined in the presence of tyramine (10 µM for DAT/NET and 100 µM for SERT). 
Assays were terminated (30 min for DAT and NET, 5 min for SERT) by rapid vacuum 
filtration/washing through GF/B filters on a Brandel harvester (Gaithersburg, MD, USA), and retained 
radioactivity was quantified by a PerkinElmer TopCount. Percent of maximal release was plotted 
against the log of compound concentration. Data were fit to a three-parameter logistic equation to 
generate EC50 values (GraphPad Prism 6.0, GraphPad Software, Inc., San Diego, CA, USA).  
 
2.6 Analysis and statistics 
All experimental data are represented as mean ± SEM. For statistical comparisons, release of 
preloaded tritiated substrate in the presence or absence of monensin was analyzed by two-way 
ANOVA (treatment x time) followed by Bonferroni’s post-hoc test. P <0.05 was chosen as the 
minimum criterion for statistical significance.  
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3. Results 
 
3.1 Fluorinated phenmetrazines inhibit transporter-mediated uptake 
2-, 3- and 4-FPM were tested for their ability to inhibit uptake mediated by hDAT, hNET or hSERT in 
HEK293 cells. As depicted in Figure 2, each compound elicited concentration-dependent inhibition of 
MAT-mediated uptake, and the relevant IC50 values are summarized in Table 1. For hDAT and hNET, 
IC50 values were in the low micromolar range, not exceeding 2.5 µM (Table 1). For hSERT, potencies 
to inhibit uptake were much weaker, with IC50 values ranging from 88 to 454 µM. The IC50 values for 
3-FPM and 4-FPM at hSERT were 111.65 (± 13.08) and 88.09 (±1.83) µM, whereas the IC50 for 2-
FPM was 454 (±15.4) µM. Notably, movement of the fluoro substitution from the 2-, to 3-, to 4-
position produced a progressive stepwise increase in relative potency at hSERT as compared to hDAT 
and hNET. This observation is best illustrated by a progressive decrease in DAT/SERT ratio and 
NET/SERT ratio (Table 1). By contrast, the DAT/NET ratio was not affected by the position of the 
fluoro substitution, with ratios close to unity for all drugs (Table 1). Overall, the IC50 values point 
toward high selectivity for catecholaminergic transporters, i.e. DAT and NET, versus SERT.  
 
 
3.2 Fluorinated phenmetrazines induce transporter-mediated reverse transport 
Although uptake inhibition assays can identify drugs which interact with MATs, the uptake assays 
cannot distinguish between drugs acting as blockers versus those acting as substrate-type releasers. 
Consequently, we examined the effects of fluorinated phenmetrazines in an efflux assay which can 
identify transporter releasers. Figure 3 shows the effects of 2-, 3- and 4-FPM on MAT-mediated 
reverse transport in HEK293. Cells expressing the desired transporter were preloaded with [
3
H]MPP
+
 
for hDAT and hNET, or [
3
H]5-HT for hSERT, and subsequently superfused. At hDAT and hNET, the 
addition of 2-, 3- or 4-FPM (5 µM each, min 2 to 10) increased tritium outflow above basal levels 
(Figure 3, closed symbols and supplementary Figure 1). At SERT, 3- and 4-FPM significantly 
enhanced basal release of [
3
H]5-HT, but 2-FPM did not (Figure 3, closed symbols and supplementary 
Figure 1). A key aspect of our efflux experiments was the pretreatment of cells with either control 
buffer or buffer containing the Na
+
/H
+
-ionophore monensin. It is well established that monensin (10 
µM) disrupts the sodium gradient across cell membranes (Mollenhauer et al., 1990), thereby 
selectively enhancing substrate-induced reverse transport via MATs (Scholze et al., 2000). As 
depicted in Figure 3, the efflux of [
3
H]substrate induced by all three fluorinated phenmetrazines at 
hDAT, hNET and hSERT was markedly enhanced by monensin (Figure 3, open symbols). A two-way 
ANOVA (treatment x time) was carried out to examine the effects of each FPM at each transporter, 
where the two treatment groups were: 1) monensin plus drug or 2) buffer plus drug.  Bonferroni post-
hoc tests were used to determine significant differences between drug with monensin as compared to 
drug without monensin at each time point. The data reveal that monensin treatment significantly 
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augmented FPM-induced [
3
H]substrate release. For 2-FPM, there was a main effect of treatment at 
hDAT F1,20=5.49, P < 0.05; hNET F1,31=14.31, P < 0.001; and hSERT F1,34=19.78, P < 0.0001. For 3-
FPM there was a main effect of treatment at hDAT F1,21= 6.82, P < 0.05; hNET F1,30=12.37, P < 0.01; 
and hSERT F1,26=66.44, P < 0.0001. And for 4-FPM there was an analogous effect of treatment at 
hDAT F1,22=8,51, P < 0.01; hNET F1,28=13,42, P < 0.001; and hSERT F1,39=25,04, P < 0.0001.  
 
 3.3. 2-,3- and 4-FPM induce transporter-mediated currents 
In DAT and NET expressing cells, 2-, 3- and 4-FPM robustly elevated the basal efflux of preloaded 
tritiated substrate and this effect could be further augmented by co-application of monensin (Figure 3). 
At SERT, however, application of the individual FPMs resulted in less marked effects. To rule out the 
possibility that the FPM-induced increases in basal tritium efflux at SERT stem from unmasked basal 
[
3
H]substrate-leakage in presence of an inhibitor, we performed electrophysiological recordings. In 
SERT-expressing cells, application of substrates results in inwardly directed currents (Mager et al., 
1994). On the contrary, this does not apply to inhibitors (Sandtner et al., 2016). As depicted in Figure 
4, application of 2-, 3- or 4-FPM, as well as the endogenous SERT-substrate 5-HT, evoked inwardly 
directed ionic currents. This was in obvious contrast to the effects observed in presence of the SERT-
inhibitor cocaine which induced no current. 
 
3.4 Effects of 2-,3- and 4-FPM on transporters in synaptosomes 
Heterologous expression of MATs in non-neuronal cells provides a convenient experimental system, 
but such conditions are artificial when compared to MATs expressed in situ. Hence, we performed 
release assays in rat brain synaptosomes (Baumann et al., 2012), an experimental system where 
transporters are expressed in their natural microenvironment including the components involved in 
neurotransmission (Gray and Whittaker, 1962, Wilhelm et al., 2014). As a means to avoid 
confounding factors associated with the vesicular accumulation of [
3
H]substrate, the release 
experiments were performed in presence of 1 µM reserpine. The data in Figure 5 demonstrate that 
fluorinated phenmetrazines act as fully efficacious releasers at MATs naturally expressed in rat brain 
synaptosomes. The findings show that the tested phenmetrazine analogues act as MAT-substrates 
rather than blockers, since “pseudo-efflux” of tritiated substrates caused by uptake blockade rarely 
exceeds 25-30% of maximal efficacy in this assay (Baumann et al., 2013).  In line with data obtained 
from HEK293 cells (Figure 2), the fluorinated phenmetrazines affected DAT and NET with 
comparable potencies. Further, as observed in HEK293 cells, a progressive decrease in the relative 
selectivity for DAT versus SERT could be detected as the fluoro substitution was moved from the 2-, 
to 3-, to 4- position. The EC50 values and the relative ratios obtained from non-linear curve fits in 
Figure 5 are summarized in Table 2. 
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4. Discussion 
 
The aim of the present study was to determine the molecular mechanism of action for the fluoro ring-
substituted analogues 2-, 3-, and 4-FPM. Previous evidence shows the parent compound 
phenmetrazine is a substrate-type releaser at DAT and NET in rat brain tissue, with much weaker 
substrate activity at SERT (Rothman et al., 2002). Solis and colleagues recently reported that 
phenmetrazine induces an inwardly-directed sodium current in cells expressing hDAT, consistent with 
its activity as a transportable DAT substrate (Solis et al., 2016). We speculated that addition of a 
fluorine substituent to the phenyl ring of phenmetrazine (Figure 1) might alter the relative potency of 
the isomers at SERT relative to DAT and NET. Data obtained here from uptake inhibition experiments 
in HEK293 cells show that the effects of FPM isomers are generally comparable to the parent 
compound phenmetrazine, with compounds exhibiting a pronounced selectivity for hDAT and hNET 
over hSERT. As depicted in Figure 2, each phenmetrazine isomer inhibited MAT-mediated uptake in 
a concentration-dependent manner. At hDAT and hNET, the test drugs potently inhibited the uptake of 
[
3
H]MPP
+
 with IC50 values in the low micromolar range. Uptake inhibition at hSERT was markedly 
less potent with corresponding IC50 values in the range of 88-445 µM (Figure 2 and Table 1). Notably, 
movement of the fluoro substitution from the 2-, to 3-, to 4-position produced a progressive stepwise 
increase in relative potency at SERT when compared to the catecholamine transporters.  
As mentioned in the Introduction, psychostimulants can be subdivided into cocaine-like 
blockers and amphetamine-like releasers. Uptake inhibition assays can be used to identify drugs that 
interact with MATs, but these assays cannot distinguish non-transported uptake inhibitors from 
transported substrates (Baumann et al., 2012). Hence, superfusion studies were performed in HEK 
cells expressing MATs to delineate the possible impact of 2-, 3- and 4-FPM on transporter-mediated 
reverse transport. These experiments allow for monitoring the time-dependent release of preloaded 
[
3
H]MPP
+
 via hDAT and hNET or [
3
H]5HT via hSERT in the absence or presence of test drugs. At 
hDAT and hNET, the fluorinated phenmetrazines had similar effects, as each FPM elevated the release 
of tritiated substrate when compared to untreated basal efflux (Figure 3). At hSERT, more divergent 
effects on release were detected with the isomers. The addition of 3- or 4-FPM induced moderate 
release of [
3
H]5HT whereas 2-FPM had no detectable effect on SERT mediated efflux at the 
concentration tested (Figure 3). The latter finding is consistent with the uptake inhibition experiments 
in which 3- and 4-FPM exerted weak but measurable inhibitory effects on SERT mediated uptake, 
whereas no obvious effect could be observed for 2-FPM at concentrations below 30 µM (Figure 2). 
The notion that the FPMs reverse the normal direction of transporter flux to induce release is bolstered 
by the fact that monensin augmented the effects on tritium overflow. Since MATs strictly depend on 
the sodium gradient as a driving force (Kristensen et al., 2011), elevated sodium concentrations at the 
cytoplasmic side of the membrane will augment efflux triggered by substrates but not blockers 
(Bonisch, 1986, Sitte and Freissmuth, 2010). At all MATs included in our study, the co-application of 
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monensin and 2-, 3- or 4-FPM resulted in a significantly higher fractional release of tritiated substrate 
in comparison to that observed in the absence of monensin (Figure 3). 
It is noteworthy that 2-, 3- and 4-FPM exerted only small effects on SERT-mediated efflux 
when given without monensin (Figure 3 and supplementary Figure 1). Earlier studies showed that 
application of a transporter blocker might artificially enhance transporter mediated efflux (i.e., pseudo-
efflux). Such an effect can be explained by the fact that an inhibitor prevents transporters from re-
capturing extracellular [
3
H]substrates that leaked from the cells by simple diffusion (Scholze et al., 
2000). In this manuscript, we provide two lines of evidence that rule out the possibility that FPMs 
might increase efflux [
3
H]5-HT via uptake blockade. First, as described above, co-application of 
monensin augmented the FPM-induced efflux several-fold (Figure 3), a phenomenon which clearly 
differentiates transportable substrates from non-transported inhibitors (Baumann et al., 2013, Sandtner 
et al., 2016, Mayer et al., 2017). Second, as observed for the endogenous SERT-substrate 5-HT, the 
presence of 2-, 3- and 4-FPM induced inwardly directed currents in SERT expressing cells (Figure 4). 
Together, these two data sets provide compelling evidence that the FPMs included in this study are 
transported by SERT in cell systems. It is worth mentioning that Scholze et al. (2000) demonstrated 
monensin causes (a) a rise in intracellular Na
+
 and (b) an alkalization of the interior of the cell. As 
such monensin is likely to i) increase transporter-mediated efflux, ii) enhance outward diffusion of the 
5HT and iii) perhaps also diminish reuptake of 5-HT via SERT. The effective release rate in the 
presence of monensin will critically depend on the rate of 5HT reuptake which may or may not fully 
compensate for the enhanced release (diffusion or carrier-mediated). The reuptake rate is determined 
mostly by the amount of transporters expressed on the cell surface, which for HEK293 cells used in 
the current study is likely to be very high due to the use of an inducible expression system. It is 
probably for this reason that the apparent release induced by monensin alone in the present work is 
considerably lower than in the earlier study of Scholze and coworkers, where a different cell line was 
used.  
 In synaptosomes prepared from native rat brain tissue, FPMs induced fully efficacious release 
of tritiated substrate in a concentration dependent manner via all three MATs. As stated above, this 
observation strongly supports the hypothesis that the effects of FPMs at DAT, NET and SERT involve 
reverse transport rather than simple uptake blockade. In accordance with uptake inhibition assays 
performed in HEK293 cells, a shift to the right could be observed for the potencies of the isomers as 
releasers of [
3
H]5HT at SERT, when compared to potencies at DAT and NET. It is predicted that the 
effects of FPMs on transporter-mediated release of tritiated substrates by DAT, NET and SERT will 
be antagonized by uptake blockers at these sites, as seen for co-application of paroxetine and PCA in 
Scholze et al., 2000.  Future studies should test this hypothesis with FPMs.  Other investigators have 
subtracted nonspecific "pseudo-efflux" caused by uptake inhibitors from total release, and considered 
a drug as a 5-HT releaser only when it produced significantly higher maximal 5-HT efflux compared 
with citalopram (Simmler et al., 2013). Importantly, the present findings from synaptosomes show that 
12 
 
ring-substitution at the 2-, 3- and 4-position produced an increase in the relative potency at SERT, i.e. 
reducing the DAT/SERT and NET/SERT ratios (Figure 5 and Table 2). Thus, the release experiments 
in synaptosomes agree with data from HEK293 cells which demonstrate that fluoro ring-substitution 
of phenmetrazine, especially at the 4-position, can increase potency at SERT relative to DAT or NET. 
This observation agrees with the findings published by Cozzi et al., (2013) who tested the effects of 
trifluoromethyl ring-substituted methcathinone analogs (Cozzi et al., 2013), showing that substitution 
at the 2-,3- and 4-positions shift the relative potencies of test drugs towards the SERT.  
 The release assays carried out in synaptosome preparations were performed in the presence of 
reserpine to block vesicular accumulation of tritiated substrates, and to exclusively observe the effects 
of the fluorinated phenmetrazines on DAT, NET and SERT. Partilla and colleagues have shown that 
the parent drug phenmetrazine does not interact with the vesicular monoamine transporter 2 (VMAT2) 
as an inhibitor or substrate at concentrations up to 100 ?M (Partilla et al., 2006). Thus, it seems 
unlikely that the fluorinated phenmetrazine analogues tested here would differ in this respect. 
Nevertheless, future studies are warranted to examine the effects of FPMs and other NPS on VMAT2 
function. 
In this study, no in vivo experiments were performed, and extrapolation of in vitro findings to 
possible effects in animals or humans must be made with caution. For example, it was previously 
shown (Rothman et al., 2002) that systemic administration of phenmetrazine results in dose-related 
elevations of extracellular dopamine and serotonin in rat nucleus accumbens, despite the fact that in 
vitro findings indicate phenmetrazine is at least 10-fold DAT-selective compared to SERT. The 
present in vitro data show that fluorination at the 2- or 3-position of phenmetrazine did not have a 
major impact on MAT activity as compared to the parent compound phenmetrazine. Thus, it is 
tempting to speculate that 3-FPM will have in vivo effects that mimic those of phenmetrazine itself. 
Indeed, user reports found on Internet forums (e.g. erowid.org, drugs-forum or bluelight.org) indicate 
3-FPM produces psychostimulant-like subjective effects in recreational human users. A recent 
publication by Backberg et al. (Backberg et al., 2016) showed that 3-FPM was found in serum and 
urine of drug abusers seeking medical care. In the cases reported by Backberg et al., stimulant-like 
neurobiological effects seem consistent with the MAT activity of 3-FPM reported here, but this 
interpretation is complicated by polydrug abuse of the individuals included in that study (Backberg et 
al., 2016).  Controlled studies would be needed to assess the clinical effects in more detail. In addition, 
no data for potential activity at receptors are available for the phenmetrazines examined in this study. 
For instance, a previous study conclusively demonstrated that the psychoactive properties of 
methcathinone analogs are attributable to their activities at MATs and not at receptors (Simmler et al., 
2014). Future studies should examine the receptor activities for FPM isomers. The data described in 
this study predict that all three phenmetrazine isomers will exert similar effects at DAT and NET, 
which could contribute to significant risk for abuse and addiction. In this study, we also included the 
2- and 4-FPM isomers which have yet to appear as “research chemicals”. Given the fluid nature of the 
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NPS phenomenon and the changes associated with “catch-up” legislation (Brandt et al., 2014), the 
appearance of 3-FPM analogues and its isomers cannot be fully excluded.  
 
5. Conclusion 
 
The “research chemical” 3-FPM, and its two positional isomers 2-FPM and 4-FPM, have been 
identified as substrate-type releasing agents at MATs. All of the FPM isomers are more selective for 
DAT and NET as compared to SERT, indicating a high potential for abuse and addiction. However, 
movement of the ring-substitution from the 2-, to 3- to 4-position produced an increase in the relative 
potency at SERT, i.e. reducing the DAT/SERT and NET/SERT ratios. This study has characterized 
the molecular mechanism of action of a current NPS and two positional isomers that could appear as 
replacements in response to banning of 3-FPM. 
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Figure 1 
 
 
Figure 1: Chemical structures of fluorophenmetrazine isomers, 2-, 3- and 4-FPM 
 
  
NH
OF
2-FPM
NH
O
3-FPM
F NH
O
4-FPM
F
19 
 
Figure 2 
 
Figure 2: Effects of fluorinated phenmetrazines on transporter-mediated uptake in HEK293 cells 
expressing human MATs. Cells were incubated with 0.02 µM [
3
H]MPP
+
 for hDAT and hNET assays 
or 0.1 µM [
3
H]5HT for hSERT assays, along with various concentrations of fluorinated 
phenmetrazines. Non-specific uptake was determined in the presence of 10 µM mazindol for DAT and 
NET or 10 µM paroxetine for SERT. All data are presented as mean ± SEM from 3 experiments 
performed in triplicate. 
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Figure 3 
 
Figure 3: Effects of fluorinated phenmetrazines on transporter-mediated efflux of tritiated substrates in 
HEK293 cells expressing human MATs. Cells were preloaded with [
3
H]MPP
+ 
for hDAT and hNET 
assays, or [
3
H]5HT for hSERT assays, and subsequently perfused. After three basal fractions 
monensin or control buffer was added at t = -8 min (MON, 10 µM, indicated by black bar). 
Subsequently, the cells were exposed to FPMs at t = 0 min (5 µM, addition at t = 0 min indicated by 
arrow). All data are represented as mean ± SEM. Data were analyzed by two-way ANOVA followed 
by Bonferroni’s test. * denotes p <0.05 when compared to the corresponding control buffer condition. 
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Figure 4 
 
 
Figure 4: Representative traces of ionic currents mediated via hSERT, recorded from the same cell (3 
different batches of cells were recorded). The three upper panels show currents induced by 30 µM 2-
FPM (-4 pA; n = 7), 10 µM 3-FPM (-3.8 pA; n = 6) and 10 µM 4-FPM (-2.5 pA; n = 7), respectively. 
These currents were inwardly directed and resembled the current induced by 30 µM 5-HT (-7 pA; n = 
3) (left lower panel). Application of cocaine (10 µM; n = 4) gave rise to an outwardly directed current, 
which presumably reflected blockage of a substrate independent leak conductance through hSERT.  
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Figure 5 
 
Figure 4: Effects of fluorinated phenmetrazines on transporter-mediated release of tritiated substrates 
from rat brain synaptosomes. Rat brain synaptosomes were preloaded with [
3
H]MPP
+
 for DAT and 
NET assays, or [
3
H]5HT for SERT assays, and subsequently exposed to various concentrations of 2-, 
3- or 4-FPM. Release assays were optimized for DAT, NET or SERT using unlabeled inhibitors as 
outlined in the materials and methods section. Data are mean ± SEM obtained from 3 experiments 
performed in triplicate. 
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Table 1 
 
IC50 (µM) 
 DAT NET SERT DAT / SERT 
ratio 
NET / SERT 
ratio 
DAT / NET 
ratio 
2-FPM 1.33 ± 0.09 1.29 ± 0.03 454 ± 15.4 340.1 351.4 0.97 
3-FPM 1.16 ± 0.29 1.51 ± 0.17 111.65 ± 13.08 96.4 73.7 1.31 
4-FPM 2.14 ± 0.39 2.05 ± 0.28 88.09 ± 1.83 41.2 42.9 0.96 
 
 
Table 1: IC50 values for inhibition of transporter-mediated uptake by FPM isomers in 
HEK293 cells. Values are given as mean ± SEM obtained from nonlinear curve fits obtained 
from n=3 independent experiments, performed in triplicate (data shown in Figure 2). 
DAT/SERT ratio is expressed as 1/(DAT IC50) divided by 1/(SERT IC50); higher values 
indicate greater selectivity for DAT. NET/SERT ratio is expressed as 1/(NET IC50) divided by 
1/(SERT IC50); higher values indicate greater selectivity for NET. DAT/NET ratio is 
expressed as 1/(DAT IC50) divided by 1/(NET IC50); higher numbers indicate greater DAT-
selectivity.  
  
24 
 
Table 2 
 
EC50 (nM) 
 DAT NET SERT DAT / SERT 
ratio 
NET / SERT 
ratio 
DAT / NET 
ratio 
2-FPM 112 ± 10 28 ± 3 4808 ± 1265 43 172 0.25 
3-FPM 60 ± 4 17 ± 4 1269 ± 207 21 75 0.28 
4-FPM 191 ± 17 58 ± 7 1895 ± 424 10 33 0.30 
 
Table 2: EC50 values for transporter-mediated release by FPM isomers in rat brain 
synaptosomes. Values are given as mean ± SEM obtained from nonlinear curve fits as shown 
in Figure 4. DAT/SERT ratio is expressed as 1/(DAT EC50) divided by 1/(SERT EC50); 
higher values indicate greater selectivity for DAT. NET/SERT ratio is expressed as 1/(NET 
EC50) divided by 1/(SERT EC50); higher values indicate greater selectivity for NET. 
DAT/NET ratio is expressed as 1/(DAT EC50) divided by 1/(NET EC50); higher numbers 
indicate greater DAT-selectivity. 
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